JP2018517415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517415A5 JP2018517415A5 JP2017564059A JP2017564059A JP2018517415A5 JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5 JP 2017564059 A JP2017564059 A JP 2017564059A JP 2017564059 A JP2017564059 A JP 2017564059A JP 2018517415 A5 JP2018517415 A5 JP 2018517415A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cell
- cells
- receptor
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 99
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 32
- 108010087819 Fc receptors Proteins 0.000 claims description 30
- 102000009109 Fc receptors Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 12
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 12
- -1 CSPG-4 Proteins 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 229960000548 alemtuzumab Drugs 0.000 claims description 6
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 6
- 229960000578 gemtuzumab Drugs 0.000 claims description 6
- 229960000575 trastuzumab Drugs 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 102100027285 Fanconi anemia group B protein Human genes 0.000 claims description 4
- 108700011146 GPA 7 Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102100022496 Mucin-5AC Human genes 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229960003008 blinatumomab Drugs 0.000 claims description 4
- 229940126590 dalatumumab Drugs 0.000 claims description 4
- 229960004137 elotuzumab Drugs 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000026725 cyclothymic disease Diseases 0.000 claims description 2
- 229960002204 daratumumab Drugs 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021036808A JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173701P | 2015-06-10 | 2015-06-10 | |
| US62/173,701 | 2015-06-10 | ||
| US201662337044P | 2016-05-16 | 2016-05-16 | |
| US62/337,044 | 2016-05-16 | ||
| PCT/US2016/036991 WO2016201304A1 (en) | 2015-06-10 | 2016-06-10 | Modified nk-92 cells for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Division JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517415A JP2018517415A (ja) | 2018-07-05 |
| JP2018517415A5 true JP2018517415A5 (OSRAM) | 2019-06-27 |
Family
ID=57504144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564059A Pending JP2018517415A (ja) | 2015-06-10 | 2016-06-10 | がんを処置するための改変ｎｋ−９２細胞 |
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Pending JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036808A Active JP7275178B2 (ja) | 2015-06-10 | 2021-03-09 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2023025723A Pending JP2023054220A (ja) | 2015-06-10 | 2023-02-22 | がんを処置するための改変ｎｋ－９２細胞 |
| JP2025048124A Pending JP2025089426A (ja) | 2015-06-10 | 2025-03-24 | がんを処置するための改変ｎｋ－９２細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10738279B2 (OSRAM) |
| EP (3) | EP4424326A3 (OSRAM) |
| JP (4) | JP2018517415A (OSRAM) |
| KR (4) | KR20250027585A (OSRAM) |
| CN (2) | CN113502270B (OSRAM) |
| AU (1) | AU2016275030B2 (OSRAM) |
| CA (1) | CA2987290C (OSRAM) |
| ES (1) | ES2958720T3 (OSRAM) |
| IL (2) | IL255884B2 (OSRAM) |
| WO (1) | WO2016201304A1 (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| JP7591342B2 (ja) | 2016-06-08 | 2024-11-28 | プレシゲン，インコーポレイテッド | Ｃｄ３３特異的キメラ抗原受容体 |
| EP3565889B1 (en) * | 2017-01-06 | 2025-03-26 | ImmunityBio, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| EP4382913A3 (en) * | 2017-01-10 | 2024-08-14 | Precigen, Inc. | Modulating expression of polypeptides via new gene switch expression systems |
| EP3576791A4 (en) * | 2017-02-01 | 2020-11-25 | Nant Holdings IP, LLC | CALRETICULIN-MEDIATION CANCER TREATMENT |
| EP3583131A4 (en) * | 2017-02-20 | 2021-03-17 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND CD33, NKG2D AND CD16 |
| EP3592845A4 (en) | 2017-03-08 | 2020-12-30 | Nantkwest, Inc. | NK-92 HANK003 MODIFIED CELLS FOR THE CLINIC |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| AU2018244221B2 (en) * | 2017-03-27 | 2021-06-03 | Nantcell, Inc. | ANK and IL-12 compositions and methods |
| WO2018186706A1 (ko) * | 2017-04-05 | 2018-10-11 | 한국생명공학연구원 | Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물 |
| AU2018251898A1 (en) * | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| TWI676483B (zh) * | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| CA3079264A1 (en) * | 2017-10-18 | 2019-04-25 | Intrexon Corporation | Polypeptide compositions comprising spacers |
| WO2019084234A1 (en) * | 2017-10-26 | 2019-05-02 | St. Jude Childen's Research Hospital, Inc. | METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS |
| EP3703735A1 (en) * | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
| EP3714040A1 (en) | 2017-11-24 | 2020-09-30 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
| CN110028589B (zh) * | 2018-02-07 | 2023-07-21 | 阿思科力(苏州)生物科技有限公司 | 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019177986A1 (en) | 2018-03-12 | 2019-09-19 | Nantkwest, Inc. | Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) |
| KR102226917B1 (ko) * | 2018-03-23 | 2021-03-11 | 주식회사 에스엘바이젠 | 신규 유전자 변형 자연살해 세포주 및 그의 용도 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| US12498363B2 (en) | 2018-08-01 | 2025-12-16 | Immunitybio, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| KR102533540B1 (ko) * | 2018-10-31 | 2023-05-17 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells) |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| US12109238B2 (en) | 2018-11-06 | 2024-10-08 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| US11547727B2 (en) * | 2018-11-06 | 2023-01-10 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
| CA3117936A1 (en) * | 2018-11-26 | 2020-06-04 | Immunitybio, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| CN119040363A (zh) * | 2019-03-15 | 2024-11-29 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CA3148608A1 (en) * | 2019-07-26 | 2021-02-04 | Immunitybio, Inc. | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis |
| SG11202103981XA (en) * | 2019-08-01 | 2021-05-28 | Nantkwest Inc | Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells |
| WO2021054789A1 (ko) * | 2019-09-18 | 2021-03-25 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| US20210106619A1 (en) * | 2019-10-10 | 2021-04-15 | Nantkwest, Inc. | NK-92 Bone and Brain targeting |
| WO2021101467A1 (en) * | 2019-11-19 | 2021-05-27 | Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ | A method for redesign and expansion of nk92 cells for use in immunotherapy |
| CN115190910A (zh) * | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
| CN113646435A (zh) | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| EP4097219A4 (en) * | 2020-01-28 | 2023-10-11 | ImmunityBio, Inc. | CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US20230074303A1 (en) * | 2020-03-28 | 2023-03-09 | Board Of Regents, The University Of Texas System | Cell immunotherapy for the treatment of cancer |
| CA3184940A1 (en) | 2020-07-07 | 2022-01-13 | Jennifer Donglan WU | Mic antibodies and binding agents and methods of using the same |
| KR20230089570A (ko) * | 2020-10-26 | 2023-06-20 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 키메라 항원 수용체 (car) nk 세포 및 이의 용도 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| WO2025158400A1 (en) * | 2024-01-24 | 2025-07-31 | Yale University | Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| AU7267398A (en) | 1997-04-30 | 1998-11-24 | Hans Klingemann | Natural killer cell lines and methods of use |
| TR200001253T2 (tr) | 1997-11-06 | 2000-11-21 | Roche Diagnostics Gmbh | Tümöre özel antijenler |
| EP1117691A1 (en) | 1998-10-05 | 2001-07-25 | Ludwig Institute For Cancer Research | Methods for producing human tumor antigen specific antibodies |
| US7098008B2 (en) | 2000-04-25 | 2006-08-29 | Ic&G Do. Ltd. | Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use |
| SE526227C2 (sv) * | 2002-05-15 | 2005-08-02 | North China Pharmaceutical Group | Metod för rening av rekombinant humant serumalbumin |
| WO2003101485A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| JP2008505071A (ja) * | 2004-07-02 | 2008-02-21 | アヴァリス・アクチエボラーグ | 細胞を遺伝学的に活性化する方法、および、該細胞の使用 |
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| DE602008006041D1 (de) | 2007-01-30 | 2011-05-19 | Forerunner Pharma Res Co Ltd | CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2656414T3 (es) | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| US9868774B2 (en) | 2011-10-20 | 2018-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014039523A1 (en) | 2012-09-04 | 2014-03-13 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| CN104853766A (zh) * | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| EP2964675B1 (en) * | 2013-03-05 | 2018-06-20 | Baylor College Of Medicine | Engager cells for immunotherapy |
| US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2014259675B2 (en) | 2013-05-03 | 2019-05-02 | Ohio State Innovation Foundation | CS1-specific chimeric antigen receptor engineered immune effector cells |
| CN104561069A (zh) * | 2013-10-23 | 2015-04-29 | 深圳先进技术研究院 | 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 |
| KR102476640B1 (ko) * | 2013-11-01 | 2022-12-09 | 이뮤너티바이오, 인크. | 종양세포 치사활성 및 항균성 조성물 및 방법 |
| DK3071222T3 (da) * | 2013-11-21 | 2020-11-16 | Ucl Business Ltd | Celle |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
-
2016
- 2016-06-10 EP EP24185893.5A patent/EP4424326A3/en active Pending
- 2016-06-10 CA CA2987290A patent/CA2987290C/en active Active
- 2016-06-10 CN CN202110790574.3A patent/CN113502270B/zh active Active
- 2016-06-10 KR KR1020257004508A patent/KR20250027585A/ko active Pending
- 2016-06-10 ES ES16808427T patent/ES2958720T3/es active Active
- 2016-06-10 KR KR1020237013832A patent/KR102627811B1/ko active Active
- 2016-06-10 US US15/531,109 patent/US10738279B2/en active Active
- 2016-06-10 CN CN201680033667.9A patent/CN107709552B/zh active Active
- 2016-06-10 EP EP16808427.5A patent/EP3307876B1/en active Active
- 2016-06-10 EP EP23176181.8A patent/EP4272757A3/en active Pending
- 2016-06-10 IL IL255884A patent/IL255884B2/en unknown
- 2016-06-10 WO PCT/US2016/036991 patent/WO2016201304A1/en not_active Ceased
- 2016-06-10 AU AU2016275030A patent/AU2016275030B2/en active Active
- 2016-06-10 KR KR1020187000382A patent/KR102526538B1/ko active Active
- 2016-06-10 KR KR1020247001893A patent/KR20240013282A/ko not_active Ceased
- 2016-06-10 JP JP2017564059A patent/JP2018517415A/ja active Pending
- 2016-06-10 IL IL309167A patent/IL309167A/en unknown
-
2020
- 2020-07-27 US US16/940,018 patent/US11788059B2/en active Active
-
2021
- 2021-03-09 JP JP2021036808A patent/JP7275178B2/ja active Active
-
2023
- 2023-02-22 JP JP2023025723A patent/JP2023054220A/ja active Pending
- 2023-09-07 US US18/463,213 patent/US20240002802A1/en active Pending
-
2025
- 2025-03-24 JP JP2025048124A patent/JP2025089426A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517415A5 (OSRAM) | ||
| Roberts et al. | Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL | |
| JP2024099850A5 (OSRAM) | ||
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| JP2020509767A5 (OSRAM) | ||
| IL278348B1 (en) | Methods and compositions for treating cancer | |
| JP2017537972A5 (OSRAM) | ||
| JP2022159548A5 (OSRAM) | ||
| JP2021137024A (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| Tay et al. | TriKEs and BiKEs join CARs on the cancer immunotherapy highway | |
| JP2016520074A5 (OSRAM) | ||
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| JP2020516654A5 (OSRAM) | ||
| JP2020530989A5 (OSRAM) | ||
| JP2021508255A5 (OSRAM) | ||
| JP2017513478A5 (OSRAM) | ||
| MX2011012047A (es) | Inmunoglobulinas humanas anti-cd52. | |
| JP2012254083A5 (OSRAM) | ||
| JP2017515460A5 (OSRAM) | ||
| JP2019532625A5 (OSRAM) | ||
| JP2015535691A5 (OSRAM) | ||
| JP2015527070A5 (OSRAM) | ||
| JP2017509342A5 (OSRAM) | ||
| JP2016534717A5 (OSRAM) | ||
| JP2014518615A5 (OSRAM) |